红细胞膜涂层的纳米载体被TGN修改为阿尔茨海默氏病的TGN
Jinlian Gu1, Chang Yan1, Shun Yin1
1School of Chemistry & Chemical Engineering, Harbin Normal University, Harbin, Heilongjiang 150025, China.
概括
这项研究开发了新的黄素载荷纳米颗粒,涂上红细胞膜和用于增强血脑屏障传输的,有效治疗阿尔茨海默病模型.
科学领域:
- 生物材料科学 生物材料科学
- 神经科学是一个神经科学.
- 纳米技术 纳米技术
背景情况:
- 阿尔茨海默病 (AD) 的特点是粉样β (Aβ) 沉积.
- 药物输送系统对于治疗AD至关重要,特别是针对大脑的向.
研究的目的:
- 开发一种红血细胞 (RBC) 膜涂层聚烯酸氨酸 (PCL) 纳米粒子系统,用于通过血脑屏障 (BBB) 传递黄素 (Cur).
- 在阿尔茨海默氏病模型中评估TGN改性纳米颗粒 (TGN-RBC-NPs-Cur) 的治疗疗效.
主要方法:
- 制造的TGN结合,红细胞膜涂层PCL纳米颗粒 (TGN-RBC-NP) 装载黄素.
- 使用共同培养的内皮细胞和星体细胞建立一个体外BBB模型.
- 在体内使用光成像,UPLC-MS/MS,行为测试和AD模型小鼠组织学分析进行体内评估.
主要成果:
- 与未经修改的NP相比,TGN-RBC-NP显示了BBB运输的八倍增加.
- 在体内观察到AD病变中黄素的显著积累.
- 在AD小鼠中,TGN-RBC-NPs-Cur治疗改善了空间学习和记忆,增加了树突脊柱密度,并减少了神经炎症.
结论:
- 该TGN-RBC-NPs-Cur系统显示了针对阿尔茨海默病治疗向大脑提供向药物的显著潜力.
- 仿生纳米系统为克服BBB和延缓AD进展提供了一个有希望的策略.
相关概念视频
01:22Alzheimer's Disease: Treatment
195
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
195
01:26Alzheimer's Disease: Overview
492
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
492